Skip to main content

Administrative Procedures & Compliance Guidelines

Conflicts of Interest

We all have conflicts at one time or another between, for example, our responsibilities to family, friends, and/or work. Having conflicts is not in itself an ethical problem. The question is how we deal with those conflicts when they arise.

In science, particular attention has been focused on the conflict between financial gain and scientific integrity. Although a case can be made that few scientists would intentionally falsify or fabricate data for the sake of a financial interest, a strong association has been repeatedly found between financial support from industry and positive findings in research. There are many possible reasons for this correlative relationship, but one important factor is unconscious individual or systemic bias. For this reason alone, it is understandable that efforts are made to identify, disclose, minimize, manage or even eliminate  financial conflicts of interest.

Whether or not a conflict is financial, the risk of bias maybe mitigated, if not eliminated, by the appropriate design and conduct of research studies. This can be accomplished, for example, by coding samples for data collection and analysis or having studies conducted to the extent possible by others who do not have the same conflicts. Doing so will help to not only protect against financial conflicts but other contributors to bias such as the desire to publish another paper, or to prove an attractive hypothesis.

Federal, state, and institutional regulations and policies are in place to require research investigators to declare financial conflicts of interest to the institutional conflict of interest office. Depending on the extent and nature of those conflicts, an investigator might be told that while a  conflict of interest exists,  the research can continue if appropriate measures are taken to manage that conflict, or that the researcher needs to minimize or eliminate that conflict before research can continue.

For more information about institutional reporting requirements and procedures, contact:

More information about conflict-of-interest policies and additional resources

Further reading about financial conflicts of interest 

  1. Bradley SG (2014): Chapter 7: Competing Interests in Research. In (Macrina FL, au): Scientific Integrity, 4th, ASM Press, Washington, DC, pp. 209-242.
  2. Friedman LS, Richter ED (2004): Relationship between conflicts of interest and research results. J Gen Intern Med 19(1):51-56
  3. Golder S, Loke YK (2008): Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol 66(6):767-73. doi: 10.1111/j.1365-2125.2008.03272.x. Epub 2008 Jul 31.
  4. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003): Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br Med J 326(7400):1167-1170
  5. Ridker PM, Torres J (2006): Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005. JAMA. 295(19):2270-2274. doi:10.1001/jama.295.19.2270.
  6. Rising K, Bacchetti P, Bero L (2008): Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 5(11):e217
  7. Sismondo S (2008): How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med 66(9):1909-1914
  8. Sismondo S (2008): Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials  29(2):109-113
  9. Stelfox HT, Chua G, O’Rourke K, Detsky AS (1998): Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med  338(2):101-106
  10. Wang AT, McCoy CP, Murad MH, Montori VM (2010): Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. Br Med J 340:c1344